Project Grant R21AI199644
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $667,643 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a malaria intelligence system and mobile decision-support application for malaria prevention and control in Kenya. The project addresses insecticide-resistant mosquito populations and outdoor biting behavior that have emerged from widespread use of long-lasting insecticide-treated...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $783,811 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize pyrroloiminoquinone alkaloid scaffolds as antimalarial and antibabesial clinical candidates. The research program aims to develop novel chemical classes for treating malaria caused by Plasmodium falciparum and babesiosis caused by Babesia species, addressing drug resistance in...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $823,548 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antimalarial and antibabesial clinical candidates based on leelamine isonitrile (GB-79). The research program will evaluate the biological activity, pharmacological properties, and mechanism of action of GB-79 and its analogues against Plasmodium falciparum and Babesia species, the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $451,000 to the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 15, 2025, with completion scheduled for July 31, 2027. This Project Grant supports the development and application of high-resolution phage immunoprecipitation sequencing (PhIP-Seq) arrays designed to comprehensively evaluate antibody responses to...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $246,000 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to quantify the contribution of malaria infections imported by agricultural populations to transmission dynamics and antimalarial drug resistance spread in Eswatini. The award funds two specific aims: improving case classification using high-resolution genomic data to...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $480,000 on September 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular basis for arboviral fitness in vector and reservoir hosts. The research examines how arboviruses replicate across evolutionarily distant hosts—insects and vertebrates—despite showing high specificity in their transmission cycles. Using alphaviruses as a...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $196,250 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to examine the vectorial capacity of invasive Anopheles stephensi mosquitoes in Ethiopia. The project investigates vector competence of invasive An. stephensi for local Plasmodium falciparum and P. vivax isolates and determines malaria vectorial capacity under field conditions in Ethiopia. An....
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $141,712 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize a novel histidine phosphotransfer system involved in the virulence of Mycobacterium tuberculosis. The funded research investigates how virulence-associated dikinase (VADK) coordinates metabolism and virulence in MTB by interacting with partner proteins. The work combines...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $301,936 on January 16, 2026, for Project Grant F32AI194808 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research investigating the role of cystatin F expression on microglia in constraining demyelination following viral infection of the central nervous system. The research uses a murine neurotropic JHM strain of mouse hepatitis virus (JHMV) model...
- The National Institute of Allergy and Infectious Diseases awarded the University of South Florida $203,060 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the ecology and transmission dynamics of Plasmodium malariae in Cameroon. The research will assess the spatial distribution and seasonal trends of P. malariae in Bangolan, a lakeshore area in Cameroon's northwest region, through molecular surveillance conducted via repeated...
The National Institute of Allergy and Infectious Diseases awarded $431,750 to the University of California Irvine on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing Project Grant R21AI199644). The award funds development and validation of a hydro-meteorological malaria model designed to improve forecasts of malaria risk in Africa and to inform tailored vector control strategies adapted to varying environmental and epidemiological conditions. The project addresses limitations in current malaria risk prediction methods, which rely either on statistical correlations that perform poorly under atypical climate scenarios such as droughts or floods, or mechanistic models that operate at coarse spatial scales and inadequately account for surface hydrology processes. The new model will incorporate mechanistic processes linking hydro-meteorological dynamics to mosquito vector ecology and malaria transmission, enabling more accurate spatial and temporal prediction of risk. This improved forecasting capability will support the design of adaptive malaria control solutions suitable for regions experiencing shifts in vector biting and resting behaviors and emerging insecticide resistance. Performance occurs in Irvine, California. The period of performance runs from September 1, 2026, through August 31, 2028. UC Irvine operates as the prime recipient. The project grant is categorized as assistance funding supporting research addressing infectious disease challenges and public health protection.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $431.8k | 8/31/26 |